Incidence of Human Immunodeficiency Virus-1 (HIV-1) Infection in HIV-1 Uninfected High Risk Men Who Have Sex With Men

NCT03310515 | Completed

• 1 other identifier: 206897
• Study Type: observational
• Target: 578
• Locations: 1 country
• Sites: 9

Brief Summary

Studies to assess the effectiveness of interventions to prevent HIV infection depend upon robust estimates of Baseline HIV incidence rates. The changing landscape of high-risk populations, as well as the evolution of biomedical pre-exposure prophylaxis (PrEP) interventions, requires a contemporary evaluation of HIV incidence as well as demographic, behavioral and other subject factors which may impact HIV incidence. This is a prospective cohort study to measure HIV-1 seroincidence in a study population of HIV-1 uninfected Chinese men who have sex with men (MSM) and transgender women (TGW) who are at high-risk of HIV infection. Approximately 550 subjects who are male sex at birth and have sex with men shall enter the study, which will allow for a 10% drop out rate to maintain 500 subjects at the conclusion of the cohort. This is a single arm cohort study to determine HIV-1 seroincidence rates in high risk MSM and TGW when combined with a comprehensive prevention package including HIV and safe sex counseling, provision of condoms and water-based lubricant, and sexually transmitted infection (STI) screening and referral for treatment. It will be determined what proportion of high-risk MSM and TGW who are given a comprehensive HIV-1 prevention package will acquire HIV-1 infection.

Conditions

Infection, Human Immunodeficiency Virus; HIV Infections

Keywords

PrEP; MSM; seroincidence; HIV-1; TGW; STIs

Outcome Measures

Primary Outcomes (2)

• HIV-1 seroincidence rate in a cohort of high-risk MSM and TGW

  Incidence of HIV-1 infection in subject's post-study entry will be assessed by determining number of subjects who become infected with HIV-1 post-screening and after study entry including Day 1 and subsequent observation visits. Confirmatory HIV serology test will be performed at seroconversion visit.

  Baseline, Day 1, Weeks 5, 9, and every 8 week intervals thereafter until study completion, an average of 12 months

• HIV-1 seroincidence rate in a cohort of high-risk TGW

  Incidence of HIV-1 infection in subject's post-study entry will be assessed by determining number of subjects who become infected with HIV-1 post-screening and after study entry including Day 1 and subsequent observation visits. Confirmatory HIV serology test will be performed at seroconversion visit.

  Baseline, Day 1, Weeks 5, 9, and every 8 week intervals thereafter until study completion, an average of 12 months

Secondary Outcomes (3)

• Number of subjects diagnosed with gonorrhea, chlamydia, and syphilis post screening

  Day 1, Week 9, and every 16 weeks interval thereafter until study completion, an average of 12 months

• Number of subjects with demographic factors

  Day 1, Week 9, and every 8 weeks interval thereafter until study completion, an average of 12 months

• Number of subjects enrolled and retained in to the study

  Day 1, Weeks 5, 9, and every 8 or 16 weeks interval thereafter until study completion, an average of 12 months

Study Arms (1)

HIV-1 uninfected high risk subjects

The study will involve HIV-1 uninfected high risk MSM and TGW subjects. They will receive comprehensive prevention package including HIV and safe sex counseling, provision of condoms and water-based lubricant, and STI screening and referral for treatment. Visits will include Baseline screening for HIV followed by screenings at Day 1, Weeks 5, 9, and 8 week intervals thereafter until study conclusion. Screening for other STIs will occur at Baseline, Week 9, and every 16 weeks thereafter.

Behavioral: Risk reduction counseling; Other: Social harm interview; Other: Computer-Assisted Self Interviewing technique

Interventions

Risk reduction counseling BEHAVIORAL

Subjects will receive comprehensive prevention package including HIV and safe sex counseling, provision of condoms and water-based lubricant, and STI screening and referral for treatment.

HIV-1 uninfected high risk subjects

Social harm interview OTHER

Information regarding social harms (loss of privacy, stigmatization, interference with gainful employment, and coercion) will be solicited during bi-monthly study visits after enrollment in the study and will be recorded. Subjects who report social harms will be referred to speak with a social worker and/or a study counselor.

HIV-1 uninfected high risk subjects

Computer-Assisted Self Interviewing technique OTHER

Demographic, behavioral, and psychosocial factors associated with HIV acquisition will be assessed by CASI.

HIV-1 uninfected high risk subjects

Eligibility Criteria

• Age: 18 Years+
• Gender Eligibility Details: Chinese MSM and/or TGW will be enrolled.
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This prospective cohort study will involve population of HIV-1 uninfected Chinese MSM and TGW who are at high-risk of HIV infection.

You may qualify if:

• Subjects are Chinese MSM and/or TGW and must be 18 years or older at the time of screening.
• Subjects of male sex at birth and who have sex with men, who in the 6 months prior to screening report one or more of the following risk criteria:
• Unprotected (condomless) receptive anal intercourse with one or more partners.
• More than five partners in the 6 months prior to enrolment (regardless of condom use and HIV serostatus, as reported by the enrolee).
• Reported STI with syphilis, gonorrhea, chlamydia, chancroid, or lymphogranuloma venereum.
• Subjects in a monogamous relationship with an HIV-1 seronegative partner or a virologically-suppressed HIV-1 + partner for \>1 year are not eligible for participation.
• Males, agree to appropriate use of contraceptive measures during heterosexual intercourse.
• Subjects who have non reactive fourth generation HIV test and undetectable HIV-1 RNA at screening.
• Capable of giving signed informed consent.

You may not qualify if:

• Subjects with known moderate to severe hepatic impairment as per liver function test criteria outlined below.
• Subject who, in the investigator's judgment, poses a significant suicide risk.
• The Subject has a tattoo or other dermatological condition overlying the gluteus region.
• Clinically significant cardiovascular disease, as defined by history/evidence of congestive heart failure, symptomatic arrhythmia, angina/ischemia, coronary artery bypass grafting (CABG) surgery or percutaneous transluminal coronary angioplasty (PTCA) or any clinically significant cardiac disease.
• Use of PrEP or post exposure prophylaxis (PEP) within the last 30 days prior to screening.
• Current use or anticipated need for use high dose aspirin or other anticoagulants including antiplatelet medications that would interfere with the ability to receive intramuscular (IM) injections.
• Exposure to an experimental drug and/or experimental vaccine within 28 days or 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to the screening.
• Anti-tuberculosis therapy.
• Alcohol use that in the judgment of the investigator would interfere with the subject's ability to complete study procedures.
• Active injection drug use that in the judgment of the investigator would interfere with the subject's ability to complete study procedures.
• Any medical condition, including psychiatric conditions, that in the judgment of the investigator would interfere with the subject's ability to complete study procedures.
• A reactive HIV test at screening.
• A positive Hepatitis B surface antigen.
• A positive Hepatitis C antibody with an HCV viral ribose nucleic acid (RNA) above the lower limit of detection.
• Any of the following laboratory values at screening:

Sponsors & Collaborators

• ViiV Healthcare: lead

Study Sites (9)

GSK Investigational Site

Guangzhou, Guangdong, 510060, China

Location

GSK Investigational Site

Shenyang, Liaoning, 110001, China

Location

GSK Investigational Site

Chengdu, Sichuan, 610066, China

Location

GSK Investigational Site

Hangzhou, Zhejiang, 310000, China

Location

GSK Investigational Site

Beijing, 100015, China

Location

GSK Investigational Site

Beijing, 100069, China

Location

GSK Investigational Site

Changsha, 410005, China

Location

GSK Investigational Site

Shanghai, 201508, China

Location

GSK Investigational Site

Shenzhen, 518020, China

Location

MeSH Terms

Conditions

Infections; Acquired Immunodeficiency Syndrome; HIV Infections; Sexually Transmitted Diseases

Condition Hierarchy (Ancestors)

Blood-Borne Infections; Communicable Diseases; Sexually Transmitted Diseases, Viral; Lentivirus Infections; Retroviridae Infections; RNA Virus Infections; Virus Diseases; Slow Virus Diseases; Genital Diseases; Urogenital Diseases; Immunologic Deficiency Syndromes; Immune System Diseases; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• GSK Clinical Trials

  ViiV Healthcare

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 21, 2017
• First Posted: October 16, 2017
• Study Start: August 31, 2017
• Primary Completion: December 31, 2018
• Study Completion: December 31, 2018
• Last Updated: March 12, 2020

Record last verified: 2020-03

Locations

CN (9)